Form 424B5
GILEAD SCIENCES INC filed this Form 424B5 on 09/14/2017
Document Outline
Entire Document (528 KB)
Subdocument 1 - 424B5 - 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - TABLE OF CONTENTS
Page 3 - ABOUT THIS PROSPECTUS SUPPLEMENT
Page 4 - WHERE YOU CAN FIND MORE INFORMATION
Page 5 - N/A
Page 6 - SUMMARY
Page 7 - Kite Pharma
Page 8 - Financing of the Acquisition
Page 9 - The Offering
Page 10 - N/A
Page 11 - N/A
Page 12 - Summary Consolidated Financial Data
Page 13 - N/A
Page 14 - RISK FACTORS
Page 15 - In the event of a special mandatory redemption, holders of the notes may not obtain their expected r
Page 16 - Our financial performance and other factors could adversely impact our ability to make payments on t
Page 17 - Risks Related to the Acquisition
Page 18 - Obtaining required regulatory approvals may prevent or delay consummation of the Tender Offer or the
Page 19 - Combining the two companies may be more difficult, costly or time consuming than we anticipate and w
Page 20 - N/A
Page 21 - FORWARD-LOOKING STATEMENTS
Page 22 - USE OF PROCEEDS
Page 23 - CAPITALIZATION
Page 24 - DESCRIPTION OF THE NOTES
Page 25 - N/A
Page 26 - Interest on the Fixed Rate Notes
Page 27 - N/A
Page 28 - Limitations on Sale and Leaseback Transactions
Page 29 - Certain Definitions
Page 30 - United States
Page 31 - Treasury Rate
Page 32 - special mandatory redemption date
Page 33 - Capital Stock
Page 34 - Change of Control Triggering Event
Page 35 - Voting Stock
Page 36 - Satisfaction, Discharge and Defeasance
Page 37 - N/A
Page 38 - Same-Day Funds Settlement and Payment
Page 39 - UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS
Page 40 - Sale, Exchange, Retirement or Other Disposition of a Note.
Page 41 - Backup Withholding and Information Reporting
Page 42 - UNDERWRITING
Page 43 - Selling Restrictions
Page 44 - Canada
Page 45 - N/A
Page 46 - LEGAL MATTERS
Page 47 - PROSPECTUS
Page 48 - TABLE OF CONTENTS
Page 49 - ABOUT THIS PROSPECTUS
Page 50 - FORWARD-LOOKING STATEMENTS
Page 51 - GILEAD SCIENCES, INC.
Page 52 - DESCRIPTION OF SECURITIES
Page 53 - Section 3.1
Page 54 - Section 3.6
Page 55 - N/A
Page 56 - Section 5.2
Page 57 - Section 5.4
Page 58 - Merger, Consolidation and Sale
Page 59 - Section 12.2
Page 60 - Section 7.2
Page 61 - Section 11.3
Page 62 - DESCRIPTION OF CAPITAL STOCK
Page 63 - Anti-Takeover Provisions
Page 64 - Exclusive Forum
Page 65 - DESCRIPTION OF WARRANTS
Page 66 - DESCRIPTION OF SUBSCRIPTION RIGHTS
Page 67 - PLAN OF DISTRIBUTION
Page 68 - LEGAL MATTERS
Page 69 - EXPERTS
Page 70 - N/A
NASDAQ (US Dollar)
$72.82
 Stock is Up 0.31 (0.43%)
Data as of 11/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Gilead Sciences at Morgan Stanley Global Healthcare Conference

September 11, 2017 9:55 a.m. ET
Play
Gilead Sciences at Citi’s 12th Annual Biotech Conference

September 06, 2017 11:00 a.m. ET
Play
Gilead Sciences Business Update

August 28, 2017 8:00 a.m. ET
Play